Adrian Quartel
Technik-/Wissenschafts-/F&E-Leiter bei ZEVRA THERAPEUTICS, INC.
Aktive Positionen von Adrian Quartel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ZEVRA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 04.01.2024 | - |
Karriereverlauf von Adrian Quartel
Ehemalige bekannte Positionen von Adrian Quartel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ACER THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 22.02.2022 | 01.01.2023 |
ADAMAS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2020 | 01.02.2022 |
BIOMARIN PHARMACEUTICAL INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2016 | 01.09.2020 |
Ausbildung von Adrian Quartel
Erasmus University Rotterdam | Doctorate Degree |
The Royal College of Physicians | Graduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Niederlande | 2 |
Vereinigtes Königreich | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 4 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
ZEVRA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Acer Therapeutics, Inc.
Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
- Börse
- Insiders
- Adrian Quartel
- Erfahrung